Ebribafusp Alfa

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Approval Year

Substance Class	Protein Created by `admin` on `Wed Apr 02 18:18:41 GMT 2025` Edited by `admin` on `Wed Apr 02 18:18:41 GMT 2025`
Protein Type	MONOCLONAL ANTIBODY FUSION PROTEIN
Protein Sub Type	IGG4
Sequence Origin	HUMANIZED MOUSE
Sequence Type	COMPLETE
Record UNII	FR7T6AM49L
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

Ebribafusp Alfa

Official Name

English

ADX-097

Preferred Name

English

ebribafusp alfa [INN]

Common Name

English

gamma 4 heavy chain (1-437) [VH (Homo sapiens IGHV1-46*01 -(IGHD) -IGHJ4*01, CDR-Kabat [5.17.2] (31-35.50-66.99-100)) (1-111) -Homo sapiens IGHG4*01 (CH1 (112-209), hinge S <sup>219</sup>>P (210-221), CH2 L <sup>226</sup>>E(222-331), CH3 M <sup>419</sup>

Common Name

English

Immunoglobulin G4 [219-proline,226-glutamic acid,419-leucine,425-serine,de-438-lysine], anti-(human complement C3d) (human-Mus musculus monoclonal ADX-097 ?4-chain) fusion protein with peptide linker ((GGGGS)2) fusion protein with 19-323-complement facto

Common Name

English

EBRIBAFUSP ALFA [USAN]

Common Name

English

Code System Code Type Description

NCI_THESAURUS

C207027

Created by admin on Wed Apr 02 18:18:41 GMT 2025 , Edited by admin on Wed Apr 02 18:18:41 GMT 2025

PRIMARY

INN

12890

Created by admin on Wed Apr 02 18:18:41 GMT 2025 , Edited by admin on Wed Apr 02 18:18:41 GMT 2025

PRIMARY

SMS_ID

300000039594

Created by admin on Wed Apr 02 18:18:41 GMT 2025 , Edited by admin on Wed Apr 02 18:18:41 GMT 2025

PRIMARY

FDA UNII

FR7T6AM49L

Created by admin on Wed Apr 02 18:18:41 GMT 2025 , Edited by admin on Wed Apr 02 18:18:41 GMT 2025

PRIMARY

USAN

NO-34

Created by admin on Wed Apr 02 18:18:41 GMT 2025 , Edited by admin on Wed Apr 02 18:18:41 GMT 2025

PRIMARY

CAS

2839652-75-2

Created by admin on Wed Apr 02 18:18:41 GMT 2025 , Edited by admin on Wed Apr 02 18:18:41 GMT 2025

PRIMARY

From	To
4_139	4_199
4_23	4_93
3_139	3_199
3_23	3_93
1_220	2_220
1_217	2_217
2_125	4_219
1_125	3_219
1_639	1_680
2_639	2_680
1_607	1_634
2_607	2_634
1_723	1_749
2_723	2_749
1_696	1_738
2_696	2_738
1_666	1_691
2_666	2_691
1_575	1_621
2_575	2_621
1_514	1_558
2_514	2_558
1_543	1_570
2_543	2_570
1_481	1_509
2_481	2_509
1_450	1_495
2_450	2_495
1_358	1_416
2_358	2_416
1_252	1_312
2_252	2_312
1_138	1_194
2_138	2_194
1_22	1_96
2_22	2_96

Glycosylation Type

MAMMALIAN

Glycosylation Link Type	Site
N	1_288
N	1_646
N	2_288
N	2_646

Related Record Type Details


					AYN2H2T5GU

Lusacomfar Alfa

TARGET->LIGAND

Interaction Type:

PRECLINICAL

Amount:


					UM18T01RY8

TARGET->LIGAND

Comments:

anti-(human complement C3d) fragment

Interaction Type:

PRECLINICAL

Amount:

Related Record Type Details


					FR7T6AM49L

Ebribafusp Alfa

ACTIVE MOIETY

Amount:

Structural Modifications

Modification Type	Location Site	Location Type	Residue Modified	Extent	Fragment Name	Fragment Approval
AMINO ACID REMOVAL	[1_752] [2_752]	C-TERMINUS	K		LYSINE	K3Z4F929H6
AMINO_ACID_SUBSTITUTION	[1_1] [2_1]	N-TERMINUS	Q		PIDOLIC ACID	SZB83O1W42

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
MOL_WEIGHT:NUMBER(CALCULATED)	CHEMICAL
MOL_WEIGHT:NUMBER(CALCULATED)	CHEMICAL
Molecular Formula	CHEMICAL
MOL_WEIGHT:NUMBER(CALCULATED)	CHEMICAL